Yeshwant Kurhe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yeshwant Kurhe has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Radhakrishnan Mahesh
Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Rajasthan, India
9 shared publicationsDeepali Gupta
Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Rajasthan 333031, India
7 shared publications- Deepali Gupta
Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Rajasthan 333031, India
7 shared publications - Mahesh Radhakrishnan
Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Rajasthan 333031, India
7 shared publications Thangaraj Devadoss
Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University (IMU), No. 126, Jalan Jalil Perkasa 19, 57000, Bukit Jalil, Kuala Lumpur, Malaysia
5 shared publicationsMahesh Radhakrishnan
Birla Institute of Technology & Science
3 shared publications
Latest Publications
- 25 February 2017
- Published by Springer Nature in Psychopharmacology
- Vol. 234 (7) , 1165-1179
Novel 5-HT3 receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice
Depression associated with obesity remains an interesting area to study the biological mechanisms and novel therapeutic intervention.
- 25 February 2017
- Published by Springer Nature in Psychopharmacology
- Vol. 234 (7) , 1165-1179
Novel 5-HT3 receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice
Depression associated with obesity remains an interesting area to study the biological mechanisms and novel therapeutic intervention.
- Open Access
- 1 January 2017
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 49 (4) , 290-296
Ondansetron ameliorates depression associated with obesity in high-fat diet fed experimental mice: An investigation-based on the behavioral, biochemical, and molecular approach
INTRODUCTION: Obesity is an important risk factor for depression as more than half of the obese population is susceptible for depression at double rate. Our earlier studies reported the antidepressant potential of 5-HT3receptor antagonist, ondansetron (OND) in depression associated obesity using behavioral tasks. The present research work is aimed to evaluate the effect of OND on depression associated with obesity with special emphasis on biochemical and molecular mechanisms such as hippocampal brain-derived neurotrophic factor (BDNF), cyclic adenosine monophosphate (cAMP), 5-hydroxytryptamine (5-HT), hippocampal histological examination and immunohistochemical expression of p53 proteins. MATERIALS AND METHODS: Mice were fed with high-fat diet (HFD) for 14 weeks, followed by treatment schedule for 28 days with vehicle/OND (0.5 and 1 mg/kg, p.o.)/reference antidepressant escitalopram (10 mg/kg, p.o.). Subsequently, animals were screened in the behavioral tests of depression such as forced swim test (FST) and sucrose preference test (SPT), biochemical estimations including hippocampal cAMP, BDNF and 5-HT, and molecular assays mainly histology and p53 expression of dentate gyrus (DG). RESULTS: HFD-fed mice showed increased immobility time in FST, reduced sucrose consumption in SPT, decreased level of signal transduction factor cAMP, neuronal growth factor BDNF and neurotransmitter 5-HT in the hippocampus, and raised and p53 expression neuronal damage in the DG region of mice fed with HFD in comparison to the mice fed with normal pellet diet. Chronic treatment with OND (0.5 and 1 mg/kg, p.o.) significantly inhibited the behavioral, biochemical and molecular modifications in HFD-fed mice. CONCLUSION: In the preliminary study, OND attenuated depression associated with obesity in mice fed with HFD using various assays procedures, at least in part by the modulation of serotonergic transmission.
- 1 January 2017
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 49 (4) , 290-296
Open AccessOndansetron ameliorates depression associated with obesity in high-fat diet fed experimental mice: An investigation-based on the behavioral, biochemical, and molecular approach
INTRODUCTION: Obesity is an important risk factor for depression as more than half of the obese population is susceptible for depression at double rate. Our earlier studies reported the antidepressant potential of 5-HT3receptor antagonist, ondansetron (OND) in depression associated obesity using behavioral tasks. The present research work is aimed to evaluate the effect of OND on depression associated with obesity with special emphasis on biochemical and molecular mechanisms such as hippocampal brain-derived neurotrophic factor (BDNF), cyclic adenosine monophosphate (cAMP), 5-hydroxytryptamine (5-HT), hippocampal histological examination and immunohistochemical expression of p53 proteins. MATERIALS AND METHODS: Mice were fed with high-fat diet (HFD) for 14 weeks, followed by treatment schedule for 28 days with vehicle/OND (0.5 and 1 mg/kg, p.o.)/reference antidepressant escitalopram (10 mg/kg, p.o.). Subsequently, animals were screened in the behavioral tests of depression such as forced swim test (FST) and sucrose preference test (SPT), biochemical estimations including hippocampal cAMP, BDNF and 5-HT, and molecular assays mainly histology and p53 expression of dentate gyrus (DG). RESULTS: HFD-fed mice showed increased immobility time in FST, reduced sucrose consumption in SPT, decreased level of signal transduction factor cAMP, neuronal growth factor BDNF and neurotransmitter 5-HT in the hippocampus, and raised and p53 expression neuronal damage in the DG region of mice fed with HFD in comparison to the mice fed with normal pellet diet. Chronic treatment with OND (0.5 and 1 mg/kg, p.o.) significantly inhibited the behavioral, biochemical and molecular modifications in HFD-fed mice. CONCLUSION: In the preliminary study, OND attenuated depression associated with obesity in mice fed with HFD using various assays procedures, at least in part by the modulation of serotonergic transmission.
- Open Access
- 1 June 2016
- Published by Elsevier in Neurobiology of Stress
- Vol. 3, 114-121
Pioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice
- 1 June 2016
- Published by Elsevier in Neurobiology of Stress
- Vol. 3, 114-121
Open AccessPioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice
- 1 November 2014
- Published by Elsevier in European Journal of Pharmacology
- Vol. 742, 94-101
Anxiolytic-like effects of alverine citrate in experimental mouse models of anxiety
- 1 November 2014
- Published by Elsevier in European Journal of Pharmacology
- Vol. 742, 94-101
Anxiolytic-like effects of alverine citrate in experimental mouse models of anxiety